A second clinical trial of a diaphragm pacer for people with ALS has shut down early, and another hangs in limbo, as doctors and patients wonder if the surgically implanted device—meant to improve ...
April 19, 2005 — Implantation of a minimally invasive diaphragm pacing system (DPS) with therapeutic electrostimulation may help maintain diaphragm function and slow or arrest the rate of respiratory ...
A pioneering trial investigating the safety and efficacy of diaphragm pacing used to alleviate breathing difficulties for people with motor neurone disease (MND), has revealed the intervention is not ...
October 14, 2010 — The US Food and Drug Administration (FDA) has granted humanitarian use device designation for a diaphragm pacing system (NeuRx; Synapse Biomedical, Inc) in patients with amyotrophic ...
Diaphragmatic pacing in conjunction with non-invasive ventilation is detrimental to patients with amyotrophic lateral sclerosis (ALS) and respiratory insufficiency, show findings from a randomised ...
ALS patients using diaphragm pacing experienced improved quality of life, with better sleep and daytime functioning, better breathing, and less fatigue. Respiratory failure is one of the major ...
Laparoscopic diaphragm mapping – an electronic reading of the diaphragm nerves – is safe and can be performed in multiple centers with success, a new study shows. Early diaphragm mapping can quickly ...
Avery Biomedical Devices, a manufacturer in Commack, is changing the lives of people around the world with its industry-leading technology: the diaphragm pacemaker. The company’s Avery Breathing ...
Respiratory failure is the principal cause of death in patients with amyotrophic lateral sclerosis (ALS), and noninvasive ventilation can prolong life by several months in these individuals.
Synapse Biomedical Inc. has won breakthrough device designation from the FDA for its Transaeris system, a diaphragm pacing system (DPS) for use in weaning patients off mechanical ventilation. The ...
Synapse Biomedical Inc. has won breakthrough device designation from the FDA for its Transaeris system, a diaphragm pacing system (DPS) for use in weaning patients off mechanical ventilation. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results